What is the difference between primary and secondary progressive MS?

Timing. Primary progressive MS is progressive from the first symptom, with no relapsing phase. Secondary progressive MS follows years of relapsing-remitting MS. Once progression is established, the two look and behave similarly, and the same principles of treatment apply.

How do I know if my relapsing MS has become secondary progressive?

The signal is steady worsening over a year or more with no relapse to explain it, usually in walking. It is recognized in hindsight, which is why measuring function at each visit matters: it turns a vague impression into a documented trend.

Is there treatment for primary progressive MS?

Yes. Ocrelizumab is approved for PPMS and slows progression, most clearly in people who are earlier in the disease and have inflammatory activity on MRI. Rehabilitation and symptom treatment also make a measurable difference, and clinical trials are testing therapies aimed at the slow injury that drives progression.

What is the life expectancy with progressive MS?

Most people with MS, including progressive MS, live into older age, and life expectancy is only modestly shorter than that of the general population, a gap that has narrowed with modern care. The bigger question is usually function, and that is where treatment, rehabilitation, and managing other health conditions have the most effect.

Can progressive MS stop progressing?

Progression can slow substantially and can plateau for long periods, particularly with treatment and in later life, when inflammation naturally quietens. Recovery of lost function is limited, which is the strongest argument for treating early and protecting what is working now.

Progressive MS: Primary and Secondary Progressive Explained

Progressive Multiple Sclerosis: Primary and Secondary Progressive MS

Progressive MS is multiple sclerosis in which disability accumulates steadily rather than in attacks. Primary progressive MS is progressive from the start; secondary progressive MS follows years of relapsing-remitting disease. Progression is driven less by new inflammation than by slow injury to nerve fibers, which is why it responds less to most disease-modifying therapies. Some therapies are approved for it, and a great deal can be done for symptoms, function, and staying active.

Medically reviewed by Dr. Achillefs Ntranos, MDPublished September 6, 20268 min read

What progressive MS is

In relapsing-remitting MS, damage arrives in episodes and the nervous system recovers in between. In progressive MS, function declines slowly and steadily, over at least a year and usually longer, without the peaks and recoveries. The two patterns reflect different biology. Relapses come from new inflammation, the kind that shows up as an enhancing lesion on MRI. Progression comes mostly from ongoing injury to nerve fibers that have already lost their myelin, from smoldering inflammation trapped inside the brain, and from the loss of the nervous system's ability to compensate. Most disease-modifying therapies were designed for the first process, which is why they help progression less.

Neurologists describe the course with two labels, and both can carry the qualifier "active" (new relapses or MRI lesions in the past year) or "not active":

Primary progressive MS (PPMS). Progressive from the beginning, with no relapsing phase. About 10 to 15 in 100 people with MS have this form. It is diagnosed later in life on average, around 40, and affects men and women about equally, unlike relapsing MS.
Secondary progressive MS (SPMS). A relapsing course that has shifted into steady worsening. The shift is gradual, and it is usually recognized in hindsight, when a year or two of slow decline can be seen with no relapse to explain it.

A single line rising slowly across the frame like a hillside, with two small early bumps and a brain silhouette at the start. — Disability climbs gradually over years, sometimes with a few relapses early on.

A softly illustrated brain and spinal cord above a continuous nerve fiber with a few areas of thinner myelin.

Symptoms

The most common story in progressive MS is a walking problem that creeps in over a year or more: one leg that drags after a distance, stairs that need a rail, a limp that a partner notices before you do. That is because progression tends to concentrate in the spinal cord, and the long nerve fibers to the legs are the most vulnerable. Other symptoms that tend to build:

Stiffness and spasms in the legs, worse at night or after sitting.
Reduced stamina. The distance you can walk shrinks, and fatigue arrives earlier.
Balance problems and a wider, more careful gait.
Bladder urgency, frequency, or incomplete emptying, and constipation.
Hand function, including fine tasks such as buttons and handwriting.
Thinking speed and memory, which decline more often in progressive than in relapsing disease.

Pain, mood changes, and sleep problems are common and treatable.

How progressive MS is recognized

There is no scan or blood test that labels MS progressive. The label comes from the timeline: a neurologist documents steady worsening over at least a year, independent of relapses, and confirms it on examination. In primary progressive MS the McDonald criteria also require MRI or spinal fluid evidence that the cause is MS rather than something else, because a slowly worsening spinal cord problem has many causes: compression, vitamin deficiencies, hereditary conditions, and other demyelinating diseases among them. A full MS evaluation works through that list before settling on the diagnosis.

Progression is measured, not guessed, and it can begin while the disease still looks relapsing, a pattern called progression independent of relapse activity. Timed walking tests, a hand-function test, cognitive screening, and a standardized disability scale at each visit turn "I think I am slower" into numbers that can be compared a year later. Newer tools, including neurofilament light chain blood tests and MRI measures of brain volume, add detail about how much damage is ongoing.

Treatment

Treatment has three aims, and each needs its own plan.

Slowing the disease. Ocrelizumab is the disease-modifying therapy approved for primary progressive MS, and siponimod is approved for active secondary progressive MS; other therapies approved for relapsing forms are used in secondary progressive MS that still shows relapses or new lesions. The benefit is a slowing of progression, not a reversal, and the trials show it is largest in people who are younger, earlier in the disease, and still have inflammatory activity on MRI. Our B-cell therapy comparison explains why ocrelizumab is the option in that class for PPMS. For non-active progressive disease, no therapy has yet shown a convincing effect, and that is where much of the current clinical trial effort is focused, including drugs that target the smoldering inflammation inside the brain.

Protecting function. Rehabilitation is not a consolation prize in progressive MS; it is one of the interventions with the best evidence for keeping people walking. Physical therapy for gait and strength, targeted exercise, treatment of spasticity, bladder management, and the right mobility aid used early rather than late all preserve independence.

Treating symptoms. Fatigue, spasms, pain, bladder symptoms, mood, and sleep each have specific treatments, and addressing them often improves daily life more than any single disease-modifying decision.

A walking cane against a chair, supportive shoes, a resistance band, a brain and spinal cord model, and an infusion bag in the background. — Disease-modifying therapy, rehabilitation, and symptom treatment each play a part.

When to see a neurologist

See an MS specialist if walking, balance, or stamina has been slowly worsening for months, whether or not you have an MS diagnosis, and if you have relapsing MS and suspect the course is changing. At our Multiple Sclerosis Clinic, Dr. Ntranos, a fellowship-trained MS specialist, reviews your history and MRI with you, measures function so change can be tracked, and works through the treatment options honestly, including trials. Visits are 60 minutes, usually the same or next day, in Beverly Hills, West Los Angeles, or by video anywhere in California. Infusions, MRI, and labs continue to run through your insurance, and we handle the prior authorizations.